RESUMO
Forty patients, mean age 56.87 yrs. with light or moderate essential arterial hypertension were randomized double-blind into two subgroups of 20 subjects each, and submitted to daily combined drug treatment with either captopril 50 mg + hydrochlorothiazide 25 mg (group A) or amiloride 5 mg + hydrochlorothiazide 50 mg (group B). Patients were monitored after the washout period and after 4 and 8 weeks of treatment approximately 20-24 after the last dose. The following parameters were studied: blood pressure, heart rate, body weight, untoward side effects. Standard laboratory tests were performed in all patients after washout and at the end of the 8-week treatment period. Both combinations significantly reduced pressure values but the captopril-hydrochlorothiazide combination reduced blood pressure more readily and proved more effective in reducing diastolic values. There were no dropouts due to subjective side effects which were of little relevance and were equally distributed among the two groups. As for laboratory data, patients taking the captopril-hydrochlorothiazide combination had a statistically significant increase in blood glucose. Neither combination induced significant changes in the other parameters, especially as far as potassemia was concerned.
Assuntos
Amilorida/administração & dosagem , Captopril/administração & dosagem , Hidroclorotiazida/administração & dosagem , Hipertensão/tratamento farmacológico , Idoso , Ensaios Clínicos como Assunto , Método Duplo-Cego , Quimioterapia Combinada , Tolerância a Medicamentos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Distribuição Aleatória , Fatores de TempoRESUMO
The authors treated 30 patients (11 females and 19 males) with cystitis or cystopyelitis. Patients were randomly assigned to one of the following treatments: a) netilmicin 200 mg daily, b) netilmicin 200 mg + ampicillin 1 g daily. Clinical and bacteriologic results were positive in all cases with resolution of clinical signs of infection and negative cultures at the end of treatment. Netilmicin alone yielded the same results as its combination with ampicillin. The safety, monitored also with netilmicin serum levels, was always good.
Assuntos
Ampicilina/uso terapêutico , Cistite/tratamento farmacológico , Netilmicina/uso terapêutico , Pielite/tratamento farmacológico , Idoso , Idoso de 80 Anos ou mais , Avaliação de Medicamentos , Quimioterapia Combinada/uso terapêutico , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Distribuição AleatóriaAssuntos
Arteriopatias Oclusivas/tratamento farmacológico , Perna (Membro)/irrigação sanguínea , Pirrolidinas/administração & dosagem , Vasodilatadores/administração & dosagem , Adulto , Idoso , Ensaios Clínicos como Assunto , Esquema de Medicação , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Distribuição AleatóriaAssuntos
Riboflavina/administração & dosagem , Tiamina/administração & dosagem , Vitamina B 12/administração & dosagem , Adulto , Idoso , Diabetes Mellitus/tratamento farmacológico , Esquema de Medicação , Feminino , Humanos , Cirrose Hepática/tratamento farmacológico , Masculino , Pessoa de Meia-Idade , Neoplasias/tratamento farmacológicoAssuntos
Deslanosídeo/metabolismo , Lanatosídeos/metabolismo , Administração Oral , Adolescente , Adulto , Idoso , Feminino , Humanos , Cinética , Masculino , Pessoa de Meia-IdadeRESUMO
N-Methyl-N-(beta-hydroxyethyl) guanidine O-phosphate (creatinol O-phosphate, COP) was checked on patients suffering from inadequate coronary circulation (12 patients had a recent myocardial infarction and 13 were suffering from angina pectoris) versus a reference substance (solvent of COP) in a double blind study. COP improved rhythm disturbances, chest pains and symptoms of contractility failure to a statistically significant degree.